Isaac J Dripps1, Qin Wang1, Richard R Neubig2, Kenner C Rice3, John R Traynor1, Emily M Jutkiewicz4. 1. Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA. 2. Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, USA. 3. Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Rockville, MD, USA. 4. Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA. ejutkiew@umich.edu.
Abstract
RATIONALE: Regulator of G protein signaling (RGS) proteins act as negative modulators of G protein signaling. RGS4 has been shown to negatively modulate G protein signaling mediated by the delta opioid receptor (DOPr) in vitro. However, the role of RGS4 in modulating DOPr-mediated behaviors in vivo has not been elucidated. OBJECTIVE: The aim of this study was to compare the ability of the DOPr agonist SNC80 to induce DOPr-mediated antinociception, antihyperalgesia, antidepressant-like effects, and convulsions in wild-type and RGS4 knockout mice. METHODS: Antinociception was assessed in the acetic acid stretch assay. Antihyperalgesia was measured in a nitroglycerin-induced thermal hyperalgesia assay. Antidepressant-like effects were evaluated in the forced swim and tail suspension tests. Mice were also observed for convulsive activity post-SNC80 treatment. SNC80-induced phosphorylation of MAP kinase in striatal tissue from RGS4 wild-type and knockout mice was quantified by Western blot. DOPr number from forebrain tissue was measured using [3H]DPDPE saturation binding. RESULTS: Elimination of RGS4 potentiated SNC80-induced antinociception and antihyperalgesia. SNC80-induced antidepressant-like effects were potentiated in RGS4 knockout mice in the forced swim test but not in the tail suspension test. Additionally, RGS4 knockout did not alter SNC80-induced convulsions. SNC80-induced phosphorylation of MAP kinase was potentiated in striatum from RGS4 knockout mice. Loss of RGS4 did not affect total DOPr number. CONCLUSIONS: Overall, these findings demonstrate that reduction of RGS4 functionally may increase the therapeutic index of SNC80. These results provide the first evidence of differential regulation of DOPr-mediated behaviors by RGS proteins and G protein signaling pathways.
RATIONALE: Regulator of G protein signaling (RGS) proteins act as negative modulators of G protein signaling. RGS4 has been shown to negatively modulate G protein signaling mediated by the delta opioid receptor (DOPr) in vitro. However, the role of RGS4 in modulating DOPr-mediated behaviors in vivo has not been elucidated. OBJECTIVE: The aim of this study was to compare the ability of the DOPr agonist SNC80 to induce DOPr-mediated antinociception, antihyperalgesia, antidepressant-like effects, and convulsions in wild-type and RGS4 knockout mice. METHODS: Antinociception was assessed in the acetic acid stretch assay. Antihyperalgesia was measured in a nitroglycerin-induced thermal hyperalgesia assay. Antidepressant-like effects were evaluated in the forced swim and tail suspension tests. Mice were also observed for convulsive activity post-SNC80 treatment. SNC80-induced phosphorylation of MAP kinase in striatal tissue from RGS4 wild-type and knockout mice was quantified by Western blot. DOPr number from forebrain tissue was measured using [3H]DPDPE saturation binding. RESULTS: Elimination of RGS4 potentiated SNC80-induced antinociception and antihyperalgesia. SNC80-induced antidepressant-like effects were potentiated in RGS4 knockout mice in the forced swim test but not in the tail suspension test. Additionally, RGS4 knockout did not alter SNC80-induced convulsions. SNC80-induced phosphorylation of MAP kinase was potentiated in striatum from RGS4 knockout mice. Loss of RGS4 did not affect total DOPr number. CONCLUSIONS: Overall, these findings demonstrate that reduction of RGS4 functionally may increase the therapeutic index of SNC80. These results provide the first evidence of differential regulation of DOPr-mediated behaviors by RGS proteins and G protein signaling pathways.
Entities:
Keywords:
Antidepressant; Antinociception; Convulsion; Delta opioid receptor; Mice; Regulator of G protein signaling 4
Authors: Jeffery N Talbot; David L Roman; Mary J Clark; Rebecca A Roof; John J G Tesmer; Richard R Neubig; John R Traynor Journal: J Neurochem Date: 2009-11-30 Impact factor: 5.372
Authors: Pattipati S Naidu; Aron H Lichtman; Carey C Archer; Everett L May; Louis S Harris; Mario D Aceto Journal: Eur J Pharmacol Date: 2007-03-30 Impact factor: 4.432
Authors: E A Bates; T Nikai; K C Brennan; Y-H Fu; A C Charles; A I Basbaum; L J Ptácek; A H Ahn Journal: Cephalalgia Date: 2010-02 Impact factor: 6.292
Authors: Isaac J Dripps; Brett T Boyer; Richard R Neubig; Kenner C Rice; John R Traynor; Emily M Jutkiewicz Journal: Br J Pharmacol Date: 2018-02-09 Impact factor: 8.739
Authors: Isaac J Dripps; Ruizhuo Chen; Amanda M Shafer; Kathryn E Livingston; Alexander Disney; Stephen M Husbands; John R Traynor; Kenner C Rice; Emily M Jutkiewicz Journal: J Pharmacol Exp Ther Date: 2020-05-28 Impact factor: 4.030
Authors: Michael Michaelides; Michael L Miller; Gabor Egervari; Stefany D Primeaux; Juan L Gomez; Randall J Ellis; Joseph A Landry; Henrietta Szutorisz; Alexander F Hoffman; Carl R Lupica; Ruth J F Loos; Panayotis K Thanos; George A Bray; John F Neumaier; Venetia Zachariou; Gene-Jack Wang; Nora D Volkow; Yasmin L Hurd Journal: Mol Psychiatry Date: 2018-06-28 Impact factor: 15.992